NasdaqGS - Delayed Quote USD

AstraZeneca PLC (AZN)

68.36 -0.17 (-0.25%)
At close: April 18 at 4:00 PM EDT
67.92 -0.44 (-0.64%)
Pre-Market: 6:14 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
45,811,000.00
45,811,000.00
44,351,000.00
37,417,000.00
26,617,000.00
Cost of Revenue
8,268,000.00
8,268,000.00
12,391,000.00
12,437,000.00
5,299,000.00
Gross Profit
37,543,000.00
37,543,000.00
31,960,000.00
24,980,000.00
21,318,000.00
Operating Expense
28,821,000.00
28,821,000.00
27,448,000.00
25,119,000.00
17,402,000.00
Operating Income
8,722,000.00
8,722,000.00
4,512,000.00
-139,000.00
3,916,000.00
Net Non Operating Interest Income Expense
-1,288,000.00
-1,288,000.00
-1,249,000.00
-1,233,000.00
-1,189,000.00
Pretax Income
6,899,000.00
6,899,000.00
2,501,000.00
-265,000.00
3,916,000.00
Tax Provision
938,000.00
938,000.00
-792,000.00
-380,000.00
772,000.00
Net Income Common Stockholders
5,955,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Diluted NI Available to Com Stockholders
5,955,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Basic EPS
1.92
--
1.06
0.04
1.22
Diluted EPS
1.91
--
1.05
0.04
1.22
Basic Average Shares
3,098,000.00
--
3,096,000.00
2,836,000.00
2,624,000.00
Diluted Average Shares
3,124,000.00
--
3,120,000.00
2,854,000.00
2,626,000.00
Total Operating Income as Reported
8,193,000.00
8,193,000.00
3,757,000.00
1,056,000.00
5,162,000.00
Rent Expense Supplemental
301,000.00
301,000.00
268,000.00
262,000.00
228,000.00
Total Expenses
37,089,000.00
37,089,000.00
39,839,000.00
37,556,000.00
22,701,000.00
Net Income from Continuing & Discontinued Operation
5,955,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Normalized Income
6,375,540.00
6,375,540.00
3,888,210.00
-852,710.00
2,192,424.92
Interest Income
301,000.00
301,000.00
81,000.00
43,000.00
83,000.00
Interest Expense
1,589,000.00
1,589,000.00
1,330,000.00
1,276,000.00
1,272,000.00
Net Interest Income
-1,288,000.00
-1,288,000.00
-1,249,000.00
-1,233,000.00
-1,189,000.00
EBIT
8,488,000.00
8,488,000.00
3,831,000.00
1,011,000.00
5,188,000.00
EBITDA
13,422,000.00
13,422,000.00
9,085,000.00
5,113,000.00
8,084,000.00
Reconciled Cost of Revenue
8,268,000.00
8,268,000.00
12,391,000.00
12,437,000.00
5,299,000.00
Reconciled Depreciation
4,934,000.00
4,934,000.00
5,254,000.00
4,102,000.00
2,896,000.00
Net Income from Continuing Operation Net Minority Interest
5,955,000.00
5,955,000.00
3,288,000.00
112,000.00
3,196,000.00
Total Unusual Items Excluding Goodwill
-489,000.00
-489,000.00
-741,000.00
1,191,000.00
1,250,000.00
Total Unusual Items
-489,000.00
-489,000.00
-741,000.00
1,191,000.00
1,250,000.00
Normalized EBITDA
13,911,000.00
13,911,000.00
9,826,000.00
3,922,000.00
6,834,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-68,460.00
-68,460.00
-140,790.00
226,290.00
246,424.92
12/31/2020 - 5/12/1993
Yahoo Finance Plus Essential access required. Unlock Access

Related Tickers

NVS Novartis AG
92.57
-0.55%
 
GSK GSK plc
39.27
-0.83%
 
SNY Sanofi
45.39
-1.56%
 
MRK Merck & Co., Inc.
125.23
-0.11%
 
BMY Bristol-Myers Squibb Company
48.30
+0.96%
 
GILD Gilead Sciences, Inc.
66.16
-1.15%
 
AMGN Amgen Inc.
262.75
-0.50%
 
ABBV AbbVie Inc.
164.66
+0.25%
 
BIIB Biogen Inc.
190.52
-0.85%
 
LLY Eli Lilly and Company
745.95
-0.64%